II. Indications
-
Prostate Cancer (advanced, metastatic, castration resistant)
- In combination with a GnRH Agonist or surgical castration
III. Mechanism
- Steroid antiandrogen that inhibits the enzyme CYP17, in the Testosterone synthesis pathway
- Decreases Testosterone synthesis at the Testes and Adrenal Glands
IV. Dosing
- Abiraterone 1000 mg orally once daily
- Combined with Prednisone 5 mg orally once to twice daily
- Decrease dose to 250 mg orally daily in moderate hepatic Impairment (Child-Pugh Class B)
V. Adverse Effects
- Cardiovascular
- Fluid retention
- Hypertension
- QTc Prolongation
- Hypertriglyceridemia or Hyperlipidemia
- Electrolytes
- Endocrine
- Gastrointestinal
- Hepatotoxicity with increased Liver Function Tests (including Alkaline Phosphatase)
- Diarrhea
- Vomiting
- Dyspepsia
- Other
- Anemia
- Fatigue
- Arthralgias
- Myalgias
VI. Safety
- Avoid in Lactation
- Avoid in pregnancy
- Women should use reliable Contraception for >=3 weeks after their male partner's last dose
VII. Drug Interactions
- Strong CYP3A4 Inducers
- Avoid with Abiraterone
-
CYP2D6 Substrates with a narrow Therapeutic Index
- Avoid with Abiraterone
VIII. Resources
IX. References
- (2022) Presc Lett, Medications to treat Prostate Cancer, Resource #380108
Images: Related links to external sites (from Bing)
Related Studies
| abiraterone (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
| ABIRATERONE ACETATE 250 MG TAB | Generic | $1.46 each |